Dongyao Pharmaceutical surged 17% in the afternoon, with "Star Market Strategy" first predicting explosive growth potential

Dongyao Pharmaceutical (1875) saw its stock price rise over 16% in the afternoon, reaching HKD 5.25. According to Sing Tao Daily, the company is expected to become a new stock that skyrockets due to a change in ownership. WuXi XDC (2268) has made a voluntary offer to acquire all shares of Dongyao Pharmaceutical, with the transaction expected to be completed in the first half of 2026. Dongyao Pharmaceutical plans to leverage WuXi XDC's brand and platform advantages to advance international operations, enhance production capacity and supply chain resilience, while also increasing R&D investment in CDMO to improve competitiveness. The projected operating revenue for 2025 is expected to be RMB 748 million, a decrease of 32%